Posts tagged buprenorphine
Titan, Opiant collaborate on new approach to opioid use disorder

Titan Pharmaceuticals (NASDAQ:TTNP) and Opiant Pharmaceuticals (NASDAQ:OPNT) are collaborating to explore development of a novel approach to the prevention of opioid relapse and overdose in individuals with opioid use disorder. 

Read More
IntelGenx film process does not infringe MonoSol patent

IntelGenx (TSXV:IGX; OTCQX:IGXT) announced that a decision by the U.S. District Court for the District of Delaware determined that the process used to manufacture IntelGenx's and Par Pharmaceutical's buprenorphine/naloxone sublingual film product for the treatment of opiate addiction does not infringe MonoSol Rx U.S. Patent No. 8,900,497. 

Read More
Titan’s Probuphine featured on CBS affiliate

The CBS affiliate in Boston, WBZ-TV, has aired a segment about the opioid crisis, featuring Probuphine, a six-month implant developed by Titan Pharmaceuticals (NASDAQ:TTNP) that releases a steady dose of buprenorphine to provide maintenance treatment for opioid addiction.

Read More
Titan Pharma implant IND cleared for Parkinson’s study

The FDA has cleared an IND application by Titan Pharmaceuticals (NASDAQ:TTNP) for its ropinirole implant intended to treat the signs and symptoms of Parkinson's disease.

Read More
Fortune hails Titan’s ProNeura technology

Fortune.com has featured Titan Pharmaceuticals (NASDAQ:TTNP) and its ProNeura technology, calling it a “formidable new class of pharmaceutical implants.”

Read More
Knight NDS for Probuphine in Canada accepted for review

Knight Therapeutics’ (TSX:GUD) New Drug Submission (NDS) for Probuphine, a subdermal implant of buprenorphine for the treatment of opioid drug dependence, has been accepted for review by Health Canada.

Read More
John Hopkins researchers discuss Titan’s Probuphine

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant of buprenorphine was featured in an article about new developments in managing opioid addiction that was published in the peer-reviewed journal, Drug, Design, Development and Therapy. 

Read More
Titan’s Probuphine featured in Fortune

The online version of Fortune magazine has produced an article about the digital health revolution that discusses the contribution of Titan Pharmaceuticals (NASDAQ:TTNP) and its Probuphine implant as a maintenance treatment for opioid addiction.

Read More
HHS to expand treatment access for war on opioid addiction

Titan Pharmaceuticals (NASDAQ:TTNP) and its marketing partner, closely-held Braeburn Pharmaceuticals, received a potential shot in the arm as the White House called for expanded access to treatment in the war on opioid addition.

Read More
Titan’s Probuphine receives patient testimonial

A patient using Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine six-month implant containing buprenorphine as a new treatment in the battle against heroin and prescription painkiller addiction has documented his experience on Janaburson’s Blog.

Read More
Braeburn gets CMS J-code for Titan's Probuphine

Closely held Braeburn Pharmaceuticals announced that the Centers for Medicare & Medicaid Services (CMS) has granted a Healthcare Common Procedure Coding System (HCPCS) code, or permanent J-code, for Probuphine, the first and only six-month buprenorphine implant for the maintenance treatment of opioid addiction.

Read More
Braeburn files for $150-million IPO

Closely held Braeburn Pharmaceuticals filed with U.S. regulators to raise up to $150-million in an initial public offering, seven months after its Probuphine implant to treat opioid addiction was approved by the FDA.

Read More
MF selects Titan’s Probuphine as a top 12 medical breakthrough

The Motley Fool investment newsletter selected Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant as one of the 12 greatest medical breakthroughs of 2016.

Read More
Titan’s Probuphine, Behshad Sheldon win Stevie awards

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant was named a gold award winner at the 13th annual Stevie Awards for Women in Business in the category of "Best New Product or Service of the Year."

Read More
Titan’s Probuphine featured at ISAM meeting

Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine implant and marketing partner, closely-held Braeburn Pharmaceuticals, were featured in three presentations at the International Society of Addiction Medicine (ISAM) annual meeting in Montreal last week.

Probuphine, a subdermal implant of buprenorphine, is the first commercially available six-month maintenance treatment for opioid dependence. The FDA approved Probuphine in May.

Read More
Popular Science picks Titan’s Probuphine for “Best of What’s New” award

Titan Pharmaceuticals’ (NASDAQ: TTNP) Probuphine implant has been recognized as one of the "12 Most Important Innovations of the Year" in the health category in Popular Science's annual Best of What's New issue.

Probuphine, a subdermal implant developed using Titan's proprietary ProNeura technology, was approved by the FDA in May, becoming the first commercially available long-term maintenance treatment of opioid dependence in clinically stable patients on 8 mg or less a day of oral buprenorphine.

Read More
Opioid addiction patient gives high marks to Titan's Probuphine

Today’s edition of USA Today carried a profile of Sarah Wilson, wife and mother of four, who became addicted to opioid pain medications after she suffered severe injuries from being hit by an intoxicated driver about eight-years-ago.

Ms. Wilson started her recovery when she entered a clinical trial that tested Titan Pharmaceuticals’ (NASDAQ:TTNP) Probuphine six-month implant of buprenorphine.

Read More